Health and Healthcare
Are Gilead Earnings Enough for Investors?
Published:
Last Updated:
Perhaps the number that most investors were watching in this report was the worldwide hepatitis C vaccine sales of $4.798 billion versus analysts’ estimates of $4.5 billion.
Product sales in the U.S. totaled $5.6 billion compared to $4.2 billion last year. In Europe, product sales rang in at $1.7 billion compared to $1.4 billion for the same period in 2014. Sales in other international locations increased to $1.0 billion compared to $327 million primarily as a result of the launch of HCV products in Japan.
On the books, Gilead had $25.1 billion in cash, cash equivalents and marketable securities compared to $14.7 billion as of June 30, 2015. This increase was primarily driven by the issuance of senior unsecured notes in September 2015 for a total aggregate principal amount of $10.0 billion. During the third quarter, the company generated $4.1 billion in operating cash flow, utilized $3.1 billion to repurchase 28 million shares and paid a cash dividend of $0.43 per share, totaling $627 million.
Separately, the company announced that the board of directors declared a cash dividend of $0.43 per share of common stock for the fourth quarter. The dividend will be payable on December 30, to stockholders of record at the close of business on December 16.
Shares of Gilead closed Tuesday up 2.1% at $110.96, with a consensus analyst price target of $124.25 and a 52-week trading range of $85.95 to $123.37. Following the release of the earnings report, shares were initially down 1.5% at $10.25 in the after-hours trading session.
ALSO READ: The 10 Most Profitable Companies in the World
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
